Multiple myeloma: therapeutic delivery of antibodies and aptamers / Neret Pujol-Navarro, Mohammed M Al Qaraghuli, Karina Kubiak-Ossowska, Manal M Alsaadi, Gillian A Horne, Richard L Soutar, Elpiniki Paspali, Valerie A Ferro, Mark TS Williams, Paul A Mulheran
Multiple myeloma is the second most common hematological malignancy in adults, accounting for 2% of all cancer-related deaths in the UK. Current chemotherapy-based regimes are insufficient, as most patients relapse and develop therapy resistance. This review focuses on current novel antibody- and aptamer-based therapies aiming to overcome current therapy limitations, as well as their respective limitations and areas of improvement. The use of computer modeling methods, as a tool to study and improve ligand-receptor alignments for the use of novel therapy development will also be discussed, as it has become a rapid, reliable and comparatively inexpensive method of investigation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
Erscheinungsort nicht ermittelbar: 2021 |
| Enthalten in: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pujol-Navarro, Neret [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Antibody–drug conjugates |
|---|
| Umfang: |
1 Online-Ressource (18 p) |
|---|
| doi: |
10.4155/tde-2021-0041 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011091878 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011091878 | ||
| 003 | DE-627 | ||
| 005 | 20230713210625.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2021-0041 |2 doi | |
| 035 | |a (DE-627)KFL011091878 | ||
| 035 | |a (KFL)prod_FICIBQ_10.4155/tde-2021-0041 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Pujol-Navarro, Neret |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multiple myeloma: therapeutic delivery of antibodies and aptamers |c Neret Pujol-Navarro, Mohammed M Al Qaraghuli, Karina Kubiak-Ossowska, Manal M Alsaadi, Gillian A Horne, Richard L Soutar, Elpiniki Paspali, Valerie A Ferro, Mark TS Williams, Paul A Mulheran |
| 264 | 1 | |a [Erscheinungsort nicht ermittelbar] |c 2021 | |
| 300 | |a 1 Online-Ressource (18 p) | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Multiple myeloma is the second most common hematological malignancy in adults, accounting for 2% of all cancer-related deaths in the UK. Current chemotherapy-based regimes are insufficient, as most patients relapse and develop therapy resistance. This review focuses on current novel antibody- and aptamer-based therapies aiming to overcome current therapy limitations, as well as their respective limitations and areas of improvement. The use of computer modeling methods, as a tool to study and improve ligand-receptor alignments for the use of novel therapy development will also be discussed, as it has become a rapid, reliable and comparatively inexpensive method of investigation | ||
| 653 | |a antibody–drug conjugates | ||
| 653 | |a antibody therapy | ||
| 653 | |a aptamer–drug conjugates | ||
| 653 | |a aptamer therapy | ||
| 653 | |a molecular docking | ||
| 653 | |a multiple myeloma | ||
| 653 | |a nanoparticles | ||
| 700 | 1 | |a Al Qaraghuli, Mohammed M |e verfasserin |4 aut | |
| 700 | 1 | |a Kubiak-Ossowska, Karina |e verfasserin |4 aut | |
| 700 | 1 | |a Alsaadi, Manal M |e verfasserin |4 aut | |
| 700 | 1 | |a Horne, Gillian A |e verfasserin |4 aut | |
| 700 | 1 | |a Soutar, Richard L |e verfasserin |4 aut | |
| 700 | 1 | |a Paspali, Elpiniki |e verfasserin |4 aut | |
| 700 | 1 | |a Ferro, Valerie A |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Mark TS |e verfasserin |4 aut | |
| 700 | 1 | |a Mulheran, Paul A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic Delivery |d London : Future Science, 2010 |h Online-Ressource |w (DE-627)KFL000006173 |w (DE-600)2590688-4 |w (DE-576)398101612 |x 2041-6008 |7 nnns |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.4155/tde-2021-0041 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||